ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 134 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,737,025 | -33.8% | 1,033,750 | -7.0% | 0.02% | -30.8% |
| Q2 2023 | $31,345,542 | +61.4% | 1,111,150 | -1.6% | 0.03% | +52.9% |
| Q1 2023 | $19,417,424 | -14.7% | 1,128,920 | -0.1% | 0.02% | -19.0% |
| Q4 2022 | $22,761,624 | -10.9% | 1,130,170 | -4.2% | 0.02% | -16.0% |
| Q3 2022 | $25,552,000 | -23.7% | 1,179,700 | -1.0% | 0.02% | -16.7% |
| Q2 2022 | $33,495,000 | -39.9% | 1,192,000 | -1.4% | 0.03% | -28.6% |
| Q1 2022 | $55,764,000 | -47.1% | 1,208,590 | -3.6% | 0.04% | -42.5% |
| Q4 2021 | $105,381,000 | +18.4% | 1,253,640 | -6.1% | 0.07% | +15.9% |
| Q3 2021 | $89,006,000 | +24.1% | 1,335,620 | -1.0% | 0.06% | +31.2% |
| Q2 2021 | $71,746,000 | +23.8% | 1,348,610 | +1.0% | 0.05% | +20.0% |
| Q1 2021 | $57,944,000 | -18.7% | 1,335,430 | -2.6% | 0.04% | -24.5% |
| Q4 2020 | $71,246,000 | +57.6% | 1,371,690 | -0.8% | 0.05% | +43.2% |
| Q3 2020 | $45,202,000 | +42.6% | 1,382,750 | +109.5% | 0.04% | +37.0% |
| Q2 2020 | $31,691,000 | – | 659,950 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
| Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
| Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
| Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
| Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
| Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
| Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
| Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
| Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
| Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |